

Hadine Joffe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5763013/publications.pdf>

Version: 2024-02-01

137
papers

7,318
citations

53939

47
h-index

68831

81
g-index

137
all docs

137
docs citations

137
times ranked

6934
citing authors

#	ARTICLE	IF	CITATIONS
1	Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition. <i>JAMA Internal Medicine</i> , 2015, 175, 531.	2.6	601
2	Sociodemographic predictors of antenatal and postpartum depressive symptoms among women in a medical group practice. <i>Journal of Epidemiology and Community Health</i> , 2006, 60, 221-227.	2.0	489
3	Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge?. <i>Biological Psychiatry</i> , 1998, 44, 798-811.	0.7	246
4	Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 267.	3.8	199
5	Estrogen therapy selectively enhances prefrontal cognitive processes. <i>Menopause</i> , 2006, 13, 411-422.	0.8	195
6	Ovarian Hormone Fluctuation, Neurosteroids, and HPA Axis Dysregulation in Perimenopausal Depression: A Novel Heuristic Model. <i>American Journal of Psychiatry</i> , 2015, 172, 227-236.	4.0	166
7	Sleep During the Perimenopause: A SWAN Story. <i>Obstetrics and Gynecology Clinics of North America</i> , 2011, 38, 567-586.	0.7	161
8	Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. <i>Menopause</i> , 2002, 9, 392-398.	0.8	160
9	Low-Dose Estradiol and the Serotonin-Norepinephrine Reuptake Inhibitor Venlafaxine for Vasomotor Symptoms. <i>JAMA Internal Medicine</i> , 2014, 174, 1058.	2.6	160
10	Evaluation and Management of Sleep Disturbance during the Menopause Transition. <i>Seminars in Reproductive Medicine</i> , 2010, 28, 404-421.	0.5	155
11	Menopause-associated Symptoms and Cognitive Performance: Results From the Study of Women's Health Across the Nation. <i>American Journal of Epidemiology</i> , 2010, 171, 1214-1224.	1.6	143
12	Clinical Advances in Sex- and Gender-Informed Medicine to Improve the Health of All. <i>JAMA Internal Medicine</i> , 2020, 180, 574.	2.6	132
13	Impact of oral contraceptive pill use on premenstrual mood: Predictors of improvement and deterioration. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 189, 1523-1530.	0.7	124
14	Gains in Body Fat and Vasomotor Symptom Reporting Over the Menopausal Transition: The Study of Women's Health Across the Nation. <i>American Journal of Epidemiology</i> , 2009, 170, 766-774.	1.6	122
15	Trajectory Clustering of Estradiol and Follicle-Stimulating Hormone during the Menopausal Transition among Women in the Study of Women's Health across the Nation (SWAN). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2872-2880.	1.8	122
16	Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. <i>Menopause</i> , 2018, 25, 1069-1085.	0.8	122
17	Sex and Gender Differences in Health: What the COVID-19 Pandemic Can Teach Us. <i>Annals of Internal Medicine</i> , 2020, 173, 385-386.	2.0	119
18	Valproate Is Associated with New-Onset Oligoamenorrhea with Hyperandrogenism in Women with Bipolar Disorder. <i>Biological Psychiatry</i> , 2006, 59, 1078-1086.	0.7	117

#	ARTICLE	IF	CITATIONS
19	Gender differences in bipolar disorder: retrospective data from the first 500 STEP-BD participants. <i>Bipolar Disorders</i> , 2005, 7, 465-470.	1.1	116
20	Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women. <i>Menopause</i> , 2006, 13, 780-786.	0.8	115
21	Eszopiclone in Patients With Insomnia During Perimenopause and Early Postmenopause. <i>Obstetrics and Gynecology</i> , 2006, 108, 1402-1410.	1.2	114
22	A Reproductive Subtype of Depression. <i>Harvard Review of Psychiatry</i> , 2009, 17, 72-86.	0.9	112
23	Telephone-Based Cognitive Behavioral Therapy for Insomnia in Perimenopausal and Postmenopausal Women With Vasomotor Symptoms. <i>JAMA Internal Medicine</i> , 2016, 176, 913.	2.6	110
24	Vasomotor Symptoms and Insulin Resistance in the Study of Women's Health Across the Nation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3487-3494.	1.8	100
25	Increased Estradiol and Improved Sleep, But Not Hot Flashes, Predict Enhanced Mood during the Menopausal Transition. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1044-E1054.	1.8	90
26	Psychotropic-Induced Hyperprolactinemia: A Clinical Review. <i>Psychosomatics</i> , 2014, 55, 29-36.	2.5	90
27	Vasomotor Symptoms and Lipid Profiles in Women Transitioning Through Menopause. <i>Obstetrics and Gynecology</i> , 2012, 119, 753-761.	1.2	88
28	COVID-19 Threatens Progress Toward Gender Equity Within Academic Medicine. <i>Academic Medicine</i> , 2021, 96, 813-816.	0.8	88
29	Treatment of Depression and Menopause-Related Symptoms With the Serotonin-Norepinephrine Reuptake Inhibitor Duloxetine. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 943-950.	1.1	81
30	Depression is associated with worse objectively and subjectively measured sleep, but not more frequent awakenings, in women with vasomotor symptoms. <i>Menopause</i> , 2009, 16, 671-679.	0.8	73
31	Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials. <i>Sleep</i> , 2018, 41, .	0.6	67
32	Menopausal quality of life: RCT of yoga, exercise, and omega-3 supplements. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 210, 244.e1-244.e11.	0.7	66
33	Antimullerian Hormone and Impending Menopause in Late Reproductive Age: The Study of Women's Health Across the Nation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1862-e1871.	1.8	66
34	Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 202, 171.e1-171.e11.	0.7	65
35	Association of Use of Oral Contraceptives With Depressive Symptoms Among Adolescents and Young Women. <i>JAMA Psychiatry</i> , 2020, 77, 52.	6.0	65
36	Algorithm and mobile app for menopausal symptom management and hormonal/non-hormonal therapy decision making. <i>Menopause</i> , 2015, 22, 247-253.	0.8	64

#	ARTICLE	IF	CITATIONS
37	Trajectories of Vasomotor Symptoms and Carotid Intima Media Thickness in the Study of Women's Health Across the Nation. <i>Stroke</i> , 2016, 47, 12-17.	1.0	63
38	Assessment and treatment of hot flushes and menopausal mood disturbance. <i>Psychiatric Clinics of North America</i> , 2003, 26, 563-580.	0.7	60
39	A Gonadotropin-Releasing Hormone Agonist Model Demonstrates That Nocturnal Hot Flashes Interrupt Objective Sleep. <i>Sleep</i> , 2013, 36, 1977-1985.	0.6	60
40	An Open Trial of Mirtazapine in Menopausal Women with Depression Unresponsive to Estrogen Replacement Therapy. <i>Journal of Women's Health and Gender-Based Medicine</i> , 2001, 10, 999-1004.	1.7	58
41	Methods for the design of vasomotor symptom trials. <i>Menopause</i> , 2014, 21, 45-58.	0.8	57
42	Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular Disease Events in SWAN. <i>Journal of the American Heart Association</i> , 2021, 10, e017416.	1.6	56
43	Effects of Estradiol and Venlafaxine on Insomnia Symptoms and Sleep Quality in Women with Hot Flashes. <i>Sleep</i> , 2015, 38, 97-108.	0.6	55
44	Longitudinal Follow-Up of Bipolar Disorder in Women With Premenstrual Exacerbation: Findings From STEP-BD. <i>American Journal of Psychiatry</i> , 2011, 168, 386-394.	4.0	53
45	Longitudinal Follow-up of Reproductive and Metabolic Features of Valproate-Associated Polycystic Ovarian Syndrome Features: A Preliminary Report. <i>Biological Psychiatry</i> , 2006, 60, 1378-1381.	0.7	50
46	Physical activity and risk of vasomotor symptoms in women with and without a history of depression. <i>Menopause</i> , 2006, 13, 553-560.	0.8	50
47	Independent Contributions of Nocturnal Hot Flashes and Sleep Disturbance to Depression in Estrogen-Deprived Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3847-3855.	1.8	50
48	Depressive symptoms across the menopause transition: findings from a large population-based cohort study. <i>Menopause</i> , 2016, 23, 1287-1293.	0.8	48
49	Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms. <i>Obstetrics and Gynecology</i> , 2015, 126, 413-422.	1.2	47
50	Hot Flash Frequency and Blood Pressure: Data from the Study of Women's Health Across the Nation. <i>Journal of Women's Health</i> , 2016, 25, 1204-1209.	1.5	47
51	Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes. <i>Menopause</i> , 2010, 17, 908-916.	0.8	45
52	Mood Symptoms After Natural Menopause and Hysterectomy With and Without Bilateral Oophorectomy Among Women in Midlife. <i>Obstetrics and Gynecology</i> , 2012, 119, 935-941.	1.2	45
53	Adverse effects of induced hot flashes on objectively recorded and subjectively reported sleep. <i>Menopause</i> , 2013, 20, 905-914.	0.8	45
54	The Impact of Depot GnRH Agonist on AMH Levels in Healthy Reproductive-Aged Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1961-E1966.	1.8	45

#	ARTICLE	IF	CITATIONS
55	Patterns of depressive disorders across 13 years and their determinants among midlife women: SWAN mental health study. <i>Journal of Affective Disorders</i> , 2016, 206, 31-40.	2.0	45
56	Objective sleep interruption and reproductive hormone dynamics in the menstrual cycle. <i>Sleep Medicine</i> , 2014, 15, 688-693.	0.8	44
57	Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. <i>Clinical Cancer Research</i> , 2021, 27, 4311-4324.	3.2	44
58	PSYCHOSOCIAL FEATURES ASSOCIATED WITH LIFETIME COMORBIDITY OF MAJOR DEPRESSION AND ANXIETY DISORDERS AMONG A COMMUNITY SAMPLE OF MID-LIFE WOMEN: THE SWAN MENTAL HEALTH STUDY. <i>Depression and Anxiety</i> , 2012, 29, 1050-1057.	2.0	41
59	Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. <i>Menopause</i> , 2020, 27, 498-505.	0.8	41
60	Sleep Trajectories Before and After the Final Menstrual Period in the Study of Women's Health Across the Nation (SWAN). <i>Current Sleep Medicine Reports</i> , 2017, 3, 235-250.	0.7	40
61	Sleep, Health, and Metabolism in Midlife Women and Menopause. <i>Obstetrics and Gynecology Clinics of North America</i> , 2018, 45, 679-694.	0.7	40
62	Menstrual Cycle Dysfunction Associated with Neurologic and Psychiatric Disorders. <i>Annals of the New York Academy of Sciences</i> , 2008, 1135, 219-229.	1.8	37
63	Lifetime History of Depression and Anxiety Disorders as a Predictor of Quality of Life in Midlife Women in the Absence of Current Illness Episodes. <i>Archives of General Psychiatry</i> , 2012, 69, 484.	13.8	37
64	Effects of Yoga and Aerobic Exercise on Actigraphic Sleep Parameters in Menopausal Women with Hot Flashes. <i>Journal of Clinical Sleep Medicine</i> , 2017, 13, 11-18.	1.4	35
65	Menstrual Dysfunction Prior to Onset of Psychiatric Illness Is Reported More Commonly by Women With Bipolar Disorder Than by Women With Unipolar Depression and Healthy Controls. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 297-304.	1.1	35
66	Treatment of Premenstrual Worsening of Depression With Adjunctive Oral Contraceptive Pills. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1954-1962.	1.1	35
67	Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: A randomized controlled trial. <i>Maturitas</i> , 2012, 73, 361-368.	1.0	34
68	Lifelong estradiol exposure and risk of depressive symptoms during the transition to menopause and postmenopause. <i>Menopause</i> , 2017, 24, 1351-1359.	0.8	33
69	Racial/ethnic disparities in women's sleep duration, continuity, and quality, and their statistical mediators: Study of Women's Health Across the Nation. <i>Sleep</i> , 2019, 42, .	0.6	33
70	Placebo Improvement in Pharmacologic Treatment of Menopausal Hot Flashes. <i>Psychosomatic Medicine</i> , 2015, 77, 167-175.	1.3	32
71	Targeting Depressive Symptoms in Younger Breast Cancer Survivors: The Pathways to Wellness Randomized Controlled Trial of Mindfulness Meditation and Survivorship Education. <i>Journal of Clinical Oncology</i> , 2021, 39, 3473-3484.	0.8	29
72	Associations between improvement in genitourinary symptoms of menopause and changes in the vaginal ecosystem. <i>Menopause</i> , 2018, 25, 500-507.	0.8	28

#	ARTICLE	IF	CITATIONS
73	Sexual Function in Women on Estradiol or Venlafaxine for Hot Flashes. <i>Obstetrics and Gynecology</i> , 2014, 124, 233-241.	1.2	27
74	The role of sleep difficulties in the vasomotor menopausal symptoms and depressed mood relationships: an international pooled analysis of eight studies in the InterLACE consortium. <i>Psychological Medicine</i> , 2018, 48, 2550-2561.	2.7	27
75	Impact of Estradiol Variability and Progesterone on Mood in Perimenopausal Women With Depressive Symptoms. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e642-e650.	1.8	27
76	Metabolic Activity in the Insular Cortex and Hypothalamus Predicts Hot Flashes: An FDG-PET Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3207-3215.	1.8	26
77	Nocturnal Hot Flashes: Relationship to Objective Awakenings and Sleep Stage Transitions. <i>Journal of Clinical Sleep Medicine</i> , 2016, 12, 1003-1009.	1.4	23
78	Sexual Function in Nondepressed Women Using Escitalopram for Vasomotor Symptoms. <i>Obstetrics and Gynecology</i> , 2012, 119, 527-538.	1.2	22
79	Enrollment of female participants in United States drug and device phase 1-3 clinical trials between 2016 and 2019. <i>Contemporary Clinical Trials</i> , 2022, 115, 106718.	0.8	22
80	Psychosocial and health-related risk factors for depressive symptom trajectories among midlife women over 15 years: Study of Women's Health Across the Nation (SWAN). <i>Psychological Medicine</i> , 2019, 49, 250-259.	2.7	21
81	A core outcome set for vasomotor symptoms associated with menopause: the COMMA (Core Outcomes) Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 111, 1000-1009.	1.1	21
82	Menopause and Mood. <i>Clinical Obstetrics and Gynecology</i> , 2004, 47, 576-591.	0.6	20
83	Duloxetine for major depressive disorder and daytime and nighttime hot flashes associated with the menopausal transition. <i>Maturitas</i> , 2013, 75, 170-174.	1.0	20
84	Effects of Escitalopram on Markers of Bone Turnover: A Randomized Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1732-E1737.	1.8	20
85	Multidimensional sleep health is not cross-sectionally or longitudinally associated with adiposity in the Study of Women's Health Across the Nation (SWAN). <i>Sleep Health</i> , 2020, 6, 790-796.	1.3	18
86	Relation of Daily Urinary Hormone Patterns to Vasomotor Symptoms in a Racially/Ethnically Diverse Sample of Midlife Women: Study of Women's Health Across the Nation. <i>Reproductive Sciences</i> , 2007, 14, 786-797.	1.1	16
87	Does midlife aging impact women's sleep duration, continuity, and timing?: A longitudinal analysis from the Study of Women's Health Across the Nation. <i>Sleep</i> , 2020, 43, .	0.6	16
88	Lights on MsFLASH: a review of contributions. <i>Menopause</i> , 2020, 27, 473-484.	0.8	16
89	Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 53-62.	1.1	15
90	Treatment of Premenstrual Breakthrough of Depression With Adjunctive Oral Contraceptive Pills Compared With Placebo. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 609-614.	0.7	14

#	ARTICLE	IF	CITATIONS
91	Predictors of irritability symptoms in mildly depressed perimenopausal women. <i>Psychoneuroendocrinology</i> , 2021, 126, 105128.	1.3	14
92	A Putative Relationship between Valproic Acid and Polycystic Ovarian Syndrome: Implications for Treatment of Women with Seizure and Bipolar Disorders. <i>Harvard Review of Psychiatry</i> , 2003, 11, 99-108.	0.9	13
93	Effects of Testosterone and Estradiol Deficiency on Vasomotor Symptoms in Hypogonadal Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3479-3486.	1.8	13
94	Confirmatory factor analysis of the Insomnia Severity Index (ISI) and invariance across race: a pooled analysis of MsFLASH data. <i>Menopause</i> , 2019, 26, 850-855.	0.8	13
95	Longitudinal Association Between Depressive Symptoms and Multidimensional Sleep Health: The SWAN Sleep Study. <i>Annals of Behavioral Medicine</i> , 2021, 55, 641-652.	1.7	13
96	Should Hormone Therapy Be Used to Prevent Depressive Symptoms During the Menopause Transition?. <i>JAMA Psychiatry</i> , 2018, 75, 125.	6.0	11
97	Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram. <i>Menopause</i> , 2013, 20, 261-268.	0.8	11
98	Associations between sleep and cognitive performance in a racially/ethnically diverse cohort: the Study of Women's Health Across the Nation. <i>Sleep</i> , 2021, 44, .	0.6	9
99	What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy. <i>Gynecologic Oncology</i> , 2021, 161, 527-534.	0.6	9
100	Reproductive biology and psychotropic treatments in premenopausal women with bipolar disorder. <i>Journal of Clinical Psychiatry</i> , 2007, 68 Suppl 9, 10-5.	1.1	9
101	The Risk of Remaining Silent: Addressing the Current Threats to Women's Health. <i>Women's Health Issues</i> , 2017, 27, 621-624.	0.9	8
102	Screening for Depression in Younger Breast Cancer Survivors: Outcomes From Use of the 9-item Patient Health Questionnaire. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab017.	1.4	8
103	Influence of the menopausal transition on polysomnographic sleep characteristics: a longitudinal analysis. <i>Sleep</i> , 2021, 44, .	0.6	8
104	Identifying women who share patterns of reproductive hormones, vasomotor symptoms, and sleep maintenance problems across the menopause transition: group-based multi-trajectory modeling in the Study of Women's Health Across the Nation. <i>Menopause</i> , 2021, 28, 126-134.	0.8	8
105	Disparate Rates of New-Onset Depression During the Menopausal Transition in 2 Community-based Populations: Real, or Really Wrong?. <i>American Journal of Epidemiology</i> , 2013, 177, 1148-1156.	1.6	7
106	OR11-03 NT-814, a Non-Hormonal Dual Neurokinin 1,3 Receptor Antagonist Markedly Improves Vasomotor Symptoms in Post-Menopausal Women; Results of a Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Study (SWITCH-1). <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	7
107	Trajectory analysis of sleep maintenance problems in midlife women before and after surgical menopause: the Study of Women's Health Across the Nation (SWAN). <i>Menopause</i> , 2020, 27, 278-288.	0.8	7
108	Plasma androgens and the presence and course of depression in a large cohort of women. <i>Translational Psychiatry</i> , 2021, 11, 124.	2.4	7

#	ARTICLE	IF	CITATIONS
109	Sleep and endocrine therapy in breast cancer. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2021, 18, 165-170.	0.6	7
110	Armodafinil for fatigue associated with menopause. <i>Menopause</i> , 2016, 23, 209-214.	0.8	6
111	Shifting Paradigms About Hormonal Risk Factors for Postmenopausal Depression. <i>JAMA Psychiatry</i> , 2016, 73, 111.	6.0	6
112	A double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated insomnia disorder in midlife women. <i>Sleep</i> , 2022, 45, .	0.6	6
113	Workshop on normal reference ranges for estradiol in postmenopausal women: commentary from The North American Menopause Society on low-dose vaginal estrogen therapy labeling. <i>Menopause</i> , 2020, 27, 611-613.	0.8	5
114	A hormonal therapy for menopausal women with MS: A phase Ib/IIa randomized controlled trial. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103747.	0.9	5
115	Cardiovascular reactivity and psychological hyperarousal in hot flash-associated insomnia disorder. <i>Menopause</i> , 2019, 26, 728-740.	0.8	4
116	Prescription medications for sleep disturbances among midlife women during 2 years of follow-up: a SWAN retrospective cohort study. <i>BMJ Open</i> , 2021, 11, e045074.	0.8	4
117	Hypothalamic-pituitary-adrenal axis, subjective, and thermal stress responses in midlife women with vasomotor symptoms. <i>Menopause</i> , 2021, 28, 439-443.	0.8	4
118	Sleep Fragmentation and Estradiol Suppression Decrease Fat Oxidation in Premenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3167-e3176.	1.8	4
119	Introduction. <i>Harvard Review of Psychiatry</i> , 2009, 17, 69-71.	0.9	3
120	Trajectory Clustering of Estradiol and Follicle-Stimulating Hormone During the Menopausal Transition Among Women in the Study of Women's Health Across the Nation (SWAN). <i>Obstetrical and Gynecological Survey</i> , 2013, 68, 361-363.	0.2	3
121	Antidepressant use after discontinuation of hormone therapy. <i>Menopause</i> , 2013, 20, 123-125.	0.8	2
122	Response to Eskola et al.. <i>American Journal of Psychiatry</i> , 2015, 172, 797-797.	4.0	2
123	Vasomotor symptoms in midlife women with incident breast cancer: pink SWAN. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 125-135.	1.1	2
124	Brain-derived neurotrophic factor and mood in perimenopausal depression. <i>Journal of Affective Disorders</i> , 2022, 300, 145-149.	2.0	2
125	Concern About the Use of Venlafaxine to Treat Vasomotor Symptoms—Reply. <i>JAMA Internal Medicine</i> , 2015, 175, 658.	2.6	1
126	Sex, Gender, and Precision Medicine—Reply. <i>JAMA Internal Medicine</i> , 2020, 180, 1129.	2.6	1

#	ARTICLE	IF	CITATIONS
127	NAMS 2019 Pre-Meeting Symposium, September 2019, Chicago Illinois: The Perimenopause. Menopause, 2020, 27, 735-745.	0.8	1
128	At menopause, what comes first: the sleepless chicken or the sex?. Menopause, 2021, 28, 606-607.	0.8	1
129	Lowered progesterone metabolite excretion and a variable LH excretion pattern are associated with vasomotor symptoms but not negative mood in the early perimenopausal transition: Study of Women's Health Across the Nation. Maturitas, 2021, 147, 26-33.	1.0	1
130	Effect of Experimentally Induced Sleep Fragmentation and Hypoestrogenism on Fasting Nutrient Utilization in Pre-Menopausal Women. Journal of the Endocrine Society, 2021, 5, A774-A774.	0.1	1
131	Sex and Gender Differences in Health. Annals of Internal Medicine, 2021, 174, 143-144.	2.0	1
132	Response to Harvey and Kornstein Letter. American Journal of Psychiatry, 2011, 168, 989-990.	4.0	0
133	Vasomotor Symptoms and Insulin Resistance in the Study of Women's Health Across the Nation. Obstetrical and Gynecological Survey, 2013, 68, 113-114.	0.2	0
134	BDNF and Mood in Perimenopausal Depression. Biological Psychiatry, 2020, 87, S368-S369.	0.7	0
135	Elinzanetant (NT-814): a novel, non-hormonal dual NK-1,3 receptor antagonist for the treatment of vasomotor symptoms - key findings from the Phase 2 SWITCH-1 study. Maturitas, 2021, 152, 71.	1.0	0
136	NAMS 2021 Utian Translational Science Symposium September 2021, Washington, DC Charting the path to health in midlife and beyond: the biology and practice of wellness. Menopause, 2022, 29, 504-513.	0.8	0
137	P688. Evoked Subjective and Hypothalamic-Pituitary-Adrenal (HPA) Axis Stress Responses in Non-Depressed Midlife Women: Relationship to Vasomotor Symptom Persistence and Insomnia. Biological Psychiatry, 2022, 91, S369.	0.7	0